Media stories about Allergan PLC. (NYSE:AGN) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Allergan PLC. earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 90 out of 100, meaning that recent press coverage is very likely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Noteworthy Monday Option Activity: VHC, AGN, BIIB (marketnewsvideo.com)
- Allergan plc Ordinary Shares (AGN) – Deutsche Bank Holds Rating And Sets New Price Target (highlightpress.com)
- Look for Shares of Allergan Plc to Potentially Pullback after Yesterday’s 1.14% Rise (mysmartrend.com)
- How Allergan’s US Specialized Therapeutics Segment Performed (finance.yahoo.com)
- Allergan PLC. (NYSE:AGN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
Shares of Allergan PLC. (NYSE:AGN) opened at 247.53 on Tuesday. Allergan PLC. has a one year low of $184.50 and a one year high of $261.27. The stock has a 50 day moving average of $231.35 and a 200-day moving average of $230.10. The firm has a market capitalization of $83.14 billion, a price-to-earnings ratio of 7.71 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Tuesday, May 9th. The company reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.32 by $0.03. The business had revenue of $3.57 billion during the quarter, compared to the consensus estimate of $3.53 billion. Allergan PLC. had a net margin of 82.42% and a return on equity of 7.29%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.04 earnings per share. On average, equities analysts anticipate that Allergan PLC. will post $16.09 earnings per share for the current fiscal year.
AGN has been the subject of several analyst reports. UBS AG reissued a “buy” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Monday, June 12th. Mizuho dropped their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Finally, Deutsche Bank AG increased their price objective on shares of Allergan PLC. from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Tuesday, March 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $273.15.
COPYRIGHT VIOLATION NOTICE: “Allergan PLC. (NYSE:AGN) Earning Somewhat Positive Media Coverage, Study Finds” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.chaffeybreeze.com/2017/07/18/somewhat-positive-media-coverage-very-likely-to-affect-allergan-plc-agn-share-price-updated-updated.html.
In related news, Director Nesli Basgoz sold 1,889 shares of the company’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.